Inventiva (IVA) Income towards Parent Company (2019 - 2021)
Inventiva (IVA) posted quarterly Income towards Parent Company of $880664.6 for Q2 2025, up 1268.27% year-over-year from $64363.5 in Q2 2024, and up 1277.33% quarter-over-quarter from -$74801.7 in Q4 2024.
Analysis
Inventiva (IVA) Income towards Parent Company (2019 - 2021) Analysis & Trends
Inventiva's Income towards Parent Company history runs 7 years deep, the most recent figure standing at $880664.6 for Q2 2025.
- In Q2 2025, Income towards Parent Company rose 1268.27% year-over-year to $880664.6; the TTM figure through Dec 2025 stood at $730480.8 (up 284.7% YoY), while the FY2025 annual figure was -$411.8 million, down 100523.69% from the prior year.
- Income towards Parent Company for Q2 2025 stood at $880664.6, up from -$74801.7 in the prior quarter.
- The five-year high for Income towards Parent Company was $880664.6 in Q2 2025, with the low at -$11.9 million in Q2 2021.
- The 5-year median for Income towards Parent Company is -$178852.7 (2022), against an average of -$2.0 million.
- The sharpest annual moves came in 2021 and 2025: Income towards Parent Company retreated 22.57% in 2021, then jumped 1268.27% in 2025.
- Inventiva's Income towards Parent Company stood at -$11.9 million in 2021, then surged by 98.03% to -$234656.9 in 2022, then retreated by 4.54% to -$245314.3 in 2023, then jumped by 69.51% to -$74801.7 in 2024, then surged by 1277.33% to $880664.6 in 2025.
- Business Quant data shows IVA's Income towards Parent Company at $880664.6 in Q2 2025, -$74801.7 in Q4 2024, and -$75382.1 in Q2 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Inventiva | 893.85 Mn | 893.85 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2021 | -11.89 Mn |
| Mar 31, 2021 | -4.44 Mn |
| Dec 31, 2020 | -40.11 Mn |
| Jun 30, 2020 | -9.70 Mn |
| Mar 31, 2020 | -7.48 Mn |
| Dec 31, 2019 | -33.40 Mn |